West Pharmaceutical Services, Inc. $WST Shares Bought by Peninsula Asset Management Inc.

Peninsula Asset Management Inc. increased its stake in West Pharmaceutical Services, Inc. (NYSE:WST) by 2.2% during the second quarter, HoldingsChannel.com reports. The fund owned 8,723 shares of the medical instruments supplier’s stock after buying an additional 190 shares during the period. Peninsula Asset Management Inc.’s holdings in West Pharmaceutical Services were worth $1,909,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of WST. Allworth Financial LP increased its stake in West Pharmaceutical Services by 229.7% in the 1st quarter. Allworth Financial LP now owns 455 shares of the medical instruments supplier’s stock worth $96,000 after purchasing an additional 317 shares in the last quarter. Ballentine Partners LLC raised its holdings in shares of West Pharmaceutical Services by 49.4% during the first quarter. Ballentine Partners LLC now owns 1,346 shares of the medical instruments supplier’s stock valued at $301,000 after acquiring an additional 445 shares during the period. Signaturefd LLC boosted its stake in West Pharmaceutical Services by 14.2% in the 1st quarter. Signaturefd LLC now owns 1,119 shares of the medical instruments supplier’s stock worth $251,000 after purchasing an additional 139 shares during the period. Apollon Wealth Management LLC grew its position in West Pharmaceutical Services by 10.5% during the 1st quarter. Apollon Wealth Management LLC now owns 1,321 shares of the medical instruments supplier’s stock worth $296,000 after purchasing an additional 126 shares in the last quarter. Finally, Dakota Wealth Management raised its stake in West Pharmaceutical Services by 37.6% during the 1st quarter. Dakota Wealth Management now owns 2,839 shares of the medical instruments supplier’s stock valued at $636,000 after purchasing an additional 776 shares during the period. 93.90% of the stock is owned by hedge funds and other institutional investors.

West Pharmaceutical Services Price Performance

NYSE WST opened at $270.37 on Monday. West Pharmaceutical Services, Inc. has a 1 year low of $187.43 and a 1 year high of $348.90. The company has a fifty day simple moving average of $266.39 and a 200 day simple moving average of $239.95. The company has a current ratio of 2.87, a quick ratio of 2.18 and a debt-to-equity ratio of 0.07. The company has a market cap of $19.45 billion, a P/E ratio of 40.05, a P/E/G ratio of 4.09 and a beta of 1.08.

West Pharmaceutical Services (NYSE:WST) last released its earnings results on Thursday, October 23rd. The medical instruments supplier reported $1.96 earnings per share for the quarter, topping analysts’ consensus estimates of $1.67 by $0.29. West Pharmaceutical Services had a net margin of 16.29% and a return on equity of 18.16%. The firm had revenue of $804.60 million during the quarter, compared to analyst estimates of $788.42 million. During the same quarter in the previous year, the business earned $1.85 EPS. The business’s revenue was up 7.7% on a year-over-year basis. West Pharmaceutical Services has set its FY 2025 guidance at 7.060-7.110 EPS. On average, sell-side analysts predict that West Pharmaceutical Services, Inc. will post 6.62 EPS for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on WST. Barclays raised their target price on West Pharmaceutical Services from $275.00 to $325.00 and gave the stock an “equal weight” rating in a research report on Monday, October 27th. Cowen assumed coverage on shares of West Pharmaceutical Services in a research report on Wednesday, October 29th. They issued a “buy” rating for the company. Zacks Research lowered shares of West Pharmaceutical Services from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 23rd. Wall Street Zen raised shares of West Pharmaceutical Services from a “hold” rating to a “buy” rating in a research note on Saturday, July 26th. Finally, KeyCorp upped their price target on shares of West Pharmaceutical Services from $325.00 to $350.00 and gave the stock an “overweight” rating in a research note on Friday, October 24th. Two research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $349.20.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.